280 Bio receives IND approval from the FDA for YL-17231

—The Company announces to initiate Phase 1 Clinical Trial with the KRAS inhibitor YL-17231 in US– SHANGHAI and SOUTH SAN FRANCISCO, Calif. , July 7, 2023 /PRNewswire/ — 280Bio, Inc. a clinical stage biotechnology company focused on the development of precision oncology medicines,…

Click here to view original post

Advertisement — Advertise with Biotech Networks